96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
<h4>Background</h4>Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings.<h4>Methods</h4>Antiretroviral...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fcec1bdc8aa6404abf2b96fb1dc669cc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fcec1bdc8aa6404abf2b96fb1dc669cc |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fcec1bdc8aa6404abf2b96fb1dc669cc2021-11-18T07:12:49Z96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.1932-620310.1371/journal.pone.0039222https://doaj.org/article/fcec1bdc8aa6404abf2b96fb1dc669cc2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22808029/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings.<h4>Methods</h4>Antiretroviral treatment-experienced patients initiating a RAL-containing salvage regimen were enrolled. Routine clinical and laboratory follow-up was performed at baseline, week 4, 12, and every 12 weeks thereafter. Data were censored at week 96.<h4>Results</h4>Out of 320 patients enrolled, 292 (91.25%) subjects maintained their initial regimen for 96 weeks; 28 discontinued prematurely for various reasons: death (11), viral failure (8), adverse events (5), loss to follow-up (3), consent withdrawal (1). Eight among these 28 subjects maintained RAL but changed the accompanying drugs. The mean CD4+ T-cell increase at week 96 was 227/mm(3); 273 out of 300 patients (91%), who were still receiving RAL at week 96, achieved viral suppression (HIV-1 RNA <50 copies/mL). When analyzing the immuno-virologic outcome according to the number of drugs used in the regimen, 2 (n = 45), 3 (n = 111), 4 (n = 124), or >4 (n = 40), CD4+ T-cell gain was similar across strata: +270, +214, +216, and +240 cells/mm(3), respectively, as was the proportion of subjects with undetectable viral load. Laboratory abnormalities (elevation of liver enzymes, total cholesterol and triglycerides) were rare, ranging from 0.9 to 3.1%. The mean 96-week total cholesterol increase was 23.6 mg/dL.<h4>Conclusions</h4>In a routine clinical setting, a RAL-based regimen allowed most patients in salvage therapy to achieve optimal viral suppression for at least 96 weeks, with relevant immunologic gain and very few adverse events.Amedeo CapettiSimona LandonioPaola MeravigliaAntonio Di BiagioSergio Lo CaputoGaetana SterrantinoAdriana AmmassariBarbara MenzaghiMarco FranzettiGiuseppe Vittorio De SocioGiovanni PellicanòElena MazzottaAlessandro SoriaMarianna MeschiariMichele TrezziLolita SassetBenedetto Maurizio CelesiaPatrizia ZucchiSara MelziElena RicciGiuliano RizzardiniPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e39222 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Amedeo Capetti Simona Landonio Paola Meraviglia Antonio Di Biagio Sergio Lo Caputo Gaetana Sterrantino Adriana Ammassari Barbara Menzaghi Marco Franzetti Giuseppe Vittorio De Socio Giovanni Pellicanò Elena Mazzotta Alessandro Soria Marianna Meschiari Michele Trezzi Lolita Sasset Benedetto Maurizio Celesia Patrizia Zucchi Sara Melzi Elena Ricci Giuliano Rizzardini 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. |
| description |
<h4>Background</h4>Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings.<h4>Methods</h4>Antiretroviral treatment-experienced patients initiating a RAL-containing salvage regimen were enrolled. Routine clinical and laboratory follow-up was performed at baseline, week 4, 12, and every 12 weeks thereafter. Data were censored at week 96.<h4>Results</h4>Out of 320 patients enrolled, 292 (91.25%) subjects maintained their initial regimen for 96 weeks; 28 discontinued prematurely for various reasons: death (11), viral failure (8), adverse events (5), loss to follow-up (3), consent withdrawal (1). Eight among these 28 subjects maintained RAL but changed the accompanying drugs. The mean CD4+ T-cell increase at week 96 was 227/mm(3); 273 out of 300 patients (91%), who were still receiving RAL at week 96, achieved viral suppression (HIV-1 RNA <50 copies/mL). When analyzing the immuno-virologic outcome according to the number of drugs used in the regimen, 2 (n = 45), 3 (n = 111), 4 (n = 124), or >4 (n = 40), CD4+ T-cell gain was similar across strata: +270, +214, +216, and +240 cells/mm(3), respectively, as was the proportion of subjects with undetectable viral load. Laboratory abnormalities (elevation of liver enzymes, total cholesterol and triglycerides) were rare, ranging from 0.9 to 3.1%. The mean 96-week total cholesterol increase was 23.6 mg/dL.<h4>Conclusions</h4>In a routine clinical setting, a RAL-based regimen allowed most patients in salvage therapy to achieve optimal viral suppression for at least 96 weeks, with relevant immunologic gain and very few adverse events. |
| format |
article |
| author |
Amedeo Capetti Simona Landonio Paola Meraviglia Antonio Di Biagio Sergio Lo Caputo Gaetana Sterrantino Adriana Ammassari Barbara Menzaghi Marco Franzetti Giuseppe Vittorio De Socio Giovanni Pellicanò Elena Mazzotta Alessandro Soria Marianna Meschiari Michele Trezzi Lolita Sasset Benedetto Maurizio Celesia Patrizia Zucchi Sara Melzi Elena Ricci Giuliano Rizzardini |
| author_facet |
Amedeo Capetti Simona Landonio Paola Meraviglia Antonio Di Biagio Sergio Lo Caputo Gaetana Sterrantino Adriana Ammassari Barbara Menzaghi Marco Franzetti Giuseppe Vittorio De Socio Giovanni Pellicanò Elena Mazzotta Alessandro Soria Marianna Meschiari Michele Trezzi Lolita Sasset Benedetto Maurizio Celesia Patrizia Zucchi Sara Melzi Elena Ricci Giuliano Rizzardini |
| author_sort |
Amedeo Capetti |
| title |
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. |
| title_short |
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. |
| title_full |
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. |
| title_fullStr |
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. |
| title_full_unstemmed |
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. |
| title_sort |
96 week follow-up of hiv-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre italian experience. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/fcec1bdc8aa6404abf2b96fb1dc669cc |
| work_keys_str_mv |
AT amedeocapetti 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT simonalandonio 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT paolameraviglia 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT antoniodibiagio 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT sergiolocaputo 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT gaetanasterrantino 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT adrianaammassari 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT barbaramenzaghi 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT marcofranzetti 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT giuseppevittoriodesocio 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT giovannipellicano 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT elenamazzotta 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT alessandrosoria 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT mariannameschiari 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT micheletrezzi 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT lolitasasset 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT benedettomauriziocelesia 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT patriziazucchi 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT saramelzi 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT elenaricci 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience AT giulianorizzardini 96weekfollowupofhivinfectedpatientsinrescuewithraltegravirplusoptimizedbackboneregimensamulticentreitalianexperience |
| _version_ |
1718423830815309824 |